2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …

E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the …

C Vrints, F Andreotti, KC Koskinas… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

[HTML][HTML] Extracorporeal life support in infarct-related cardiogenic shock

H Thiele, U Zeymer, I Akin, M Behnes… - … England Journal of …, 2023 - Mass Medical Soc
Background Extracorporeal life support (ECLS) is increasingly used in the treatment of
infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality …

[HTML][HTML] Catheter ablation in end-stage heart failure with atrial fibrillation

C Sohns, H Fox, NF Marrouche… - … England Journal of …, 2023 - Mass Medical Soc
Background The role of catheter ablation in patients with symptomatic atrial fibrillation and
end-stage heart failure is unknown. Methods We conducted a single-center, open-label trial …

2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) …

IC Van Gelder, M Rienstra, KV Bunting… - European Heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …

N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure …

JW McEvoy, CP McCarthy, RM Bruno… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …

G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised …

A Mebazaa, B Davison, O Chioncel, A Cohen-Solal… - The Lancet, 2022 - thelancet.com
Background There is a paucity of evidence for dose and pace of up-titration of guideline-
directed medical therapies after admission to hospital for acute heart failure. Methods In this …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …